prostate tissue News
-
C4 Imaging Announces an Additional FDA 510(k) Clearance for its Positive-Signal MRI Marker - Sirius
C4 Imaging LLC is pleased to announce an additional US Food and Drug Administration 510(k) clearance for its Sirius MRI Marker, a novel positive-signal MRI Marker that is used during the treatment of prostate cancer with brachytherapy. This additional 510(k) clears Sirius MRI Markers to be sterilized with ethylene oxide. Previously only gamma sterilization was available; the addition of ethylene ...
-
« Back Northside Healthcare System in Atlanta Advances Surgical Robotics Program with Multi-System, Multi-Hospital Agreement for PROCEPT BioRobotics AquaBeam Systems
First and only image-guided, heat-free surgical robotic procedure aims to establish a new standard of care for patients with enlarged prostates REDWOOD CITY, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it now has five ...
-
Zenflow Announces $24 Million Financing Round; Appoints Susan Stimson as President
Zenflow, Inc., a medical device company developing a minimally invasive treatment for urinary obstruction caused by enlarged prostate, or benign prostatic hyperplasia (BPH), today announced that it has closed a $24 million Series B financing round. The funding was led by Invus Opportunities and included participation from F-Prime Capital, Medical Technology Venture Partners, Golden Seeds, Astia ...
-
24 Aug 2010: atrazine causes prostate inflammation in male rats and delays puberty
A new study shows that male rats prenatally exposed to low doses of atrazine, a widely used herbicide, are more likely to develop prostate inflammation and to go through puberty later than non-exposed animals. The research adds to a growing body of literature on atrazine, a herbicide predominantly used to control weeds and grasses in crops such as corn and sugar cane. Atrazine and its byproducts ...
-
Profound Medical Announces First Patients Treated in Prospective, Randomized Clinical Trial Comparing the TULSA Procedure to Radical Prostatectomy
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that the first patients have been treated in the Level 1 ‘CAPTAIN’ trial. CAPTAIN (A Comparison of TULSA Procedure vs. Radical ...
-
How Technology, Early Diagnoses Can Help Turn the Tide on Prostate Cancer Prognosis
Dr. Ali Tinazli's post at the Forbes magazine about "How Technology, Early Diagnoses Can Help Turn The Tide On Prostate Cancer Prognosis" There has never been more hope or promise in the global effort to eradicate cancer. Confidence in finding lifesaving cures is at an all-time high among medical researchers who work tirelessly for a solution. Astounding ...
-
Announcement – New AI Tool for Prostate MRI Analysis to Support PI-RADS Scoring
Innovative technology performs automatic segmentation and lesion detection in prostate MRI scans to assist in PI-RADS scoring for prostate cancer management. RSIP Vision, an experienced leader in driving innovation for medical imaging through advanced Artificial Intelligence (AI) and computer vision solutions, today announces a new tool for prostate MRI analysis. The tool performs segmentation ...
By RSIP Vision
-
Profound Medical’s TULSA-PRO® Now Compatible with GE Healthcare’s 3T MRI Scanners
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today confirmed the TULSA-PRO® system’s new compatibility with GE Healthcare’s 3T Magnetic Resonance Imaging (“MRI”) scanners. ...
-
The Ultimate List of Attractive MedTech M&A Targets
Updated May 12, 2021 to reflect 10 new additions, based on recent analyst reports. We’ve also updated the existing companies on the list to reflect recent business developments. From time to time, medtech analysts will call out companies in the private sector that they believe investors should be keeping tabs on. Here is our ultimate list, compiled from analyst reports, of private ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you